Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) EPS (Basic) (2022 - 2025)

Summit Therapeutics (SMMT) has disclosed EPS (Basic) for 4 consecutive years, with -$0.28 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) fell 211.11% year-over-year to -$0.28, compared with a TTM value of -$1.44 through Dec 2025, down 350.0%, and an annual FY2025 reading of -$1.44, down 364.52% over the prior year.
  • EPS (Basic) was -$0.28 for Q4 2025 at Summit Therapeutics, up from -$0.31 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.4 in Q2 2023 and bottomed at -$1.43 in Q1 2023.
  • Average EPS (Basic) over 4 years is -$0.22, with a median of -$0.09 recorded in 2024.
  • The sharpest move saw EPS (Basic) skyrocketed 150.0% in 2023, then crashed 800.0% in 2024.
  • Year by year, EPS (Basic) stood at -$0.1 in 2022, then soared by 90.0% to -$0.01 in 2023, then crashed by 800.0% to -$0.09 in 2024, then crashed by 211.11% to -$0.28 in 2025.
  • Business Quant data shows EPS (Basic) for SMMT at -$0.28 in Q4 2025, -$0.31 in Q3 2025, and -$0.76 in Q2 2025.